Known targets — ChEMBL curated mechanism
ADRB1ADRB2SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Propafenone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.96 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.96 |
| ▸ | ABCB1 | P08183 | 17/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.96 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.96 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | HTR2C | P28335 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propafenone SCHEMBL41413 | 0.98 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL27865 | 0.98 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL16730120 | 0.98 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL30416841 | 0.98 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL5529275 | 0.97 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL41412 | 0.97 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL29384899 | 0.97 | MEN1 (1.00) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL29419081 | 0.92 | ABCB1 (0.88) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL15539494 | 0.89 | ABCB1 (0.83) | ABCB1LMNACYP1A2CYP2D6CYP3A4 | |
| Propafenone SCHEMBL924632 | 0.87 | ABCB1 (0.79) | ABCB1LMNACYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656189-A1 | COMPOUND AND USE THEREOF | Benethera (Shaoxing) Biotechnology Co., Ltd. (CN) | 2025-12-03 | — | — | EP | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| US-20190336490-A1 | COMPOSITIONS AND METHODS FOR INCREASING REMYELINATION | Frequency Therapeutics, Inc. | 2019-11-07 | — | — | US | disclosed |
| US-20190262353-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2019-08-29 | — | — | US | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20140221286-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| EP-2758053-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | Gilead Sciences, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| WO-2013043925-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1817427-B1 | METHOD FOR DETERMINING GENOTOXICITY | HOFFMANN LA ROCHE (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7745152-B2 | Method for determining genotoxicity | ROCHE PALO ALTO LLC (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| CN-101065501-A | Method for determining genotoxicity | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | CN | disclosed |
| US-20060110768-A1 | Method for determining genotoxicity | ROCHE PALO ALTO LLC | 2006-05-25 | — | — | US | disclosed |
| EP-1239280-A2 | ElogDoct:A tool for lipophilicity determination in drug discovery basic and neutral compounds | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221286-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | IAPP, SCNN1B, GLP1R | ADRB2 137/4885ADRB1 95/4885SCN5A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.